NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
Clinical Trials
3 trialsNCT03403712 2020-06-01
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Helsinn Healthcare SA
Phase 3 Completed
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed